Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tailored lipid nanoparticles for iontophoretic ocular drug delivery.

Project description

New drug delivery system for retinal disorders

Retinal disorders, including age-related macular oedema and diabetic retinopathies, are amongst the major causes of blindness. Effective treatment often requires monthly ocular injections, which can cause harmful side effects and pain. This is why some patients avoid or discontinue treatment. Supported by the Marie Skłodowska-Curie Actions programme, the ODiN project will develop a drug delivery system using lipid nanoparticles (LNPs) combined with trans-scleral iontophoresis to enhance drug penetration into the eye for the treatment of retinal disorders. It will use statin-loaded LNPs, repurposing them for their pleiotropic properties. Research will focus on their design, formulation and testing with isolated porcine eyes, following ethical guidelines. The goal is to create a sustainable system that reduces the need for invasive treatments.

Objective

Retinal disorders such as age-related macular edema, diabetic retinopathies, retinitis pigmentosa and glaucoma are among the leading causes of irreversible blindness worldwide. Currently, effective drug therapy is hindered due to anatomical and physiological characteristics of the eye, thus requiring ocular injections to ensure drug concentration to ensure therapeutic effect. These injections are administered monthly and associated with severe side effects, including retinal detachment, infections, cataracts, hemorrhage, increased intraocular pressure, and ultimately significant patient discomfort and drop out. To overcome this aspect the ODiN project aims to develop a novel drug delivery platform that combines surface-tailored lipid nanoparticles (LNPs) with trans-scleral iontophoresis (IOF), a mild electric current technique that enhances drug penetration.Thus the amount of drug penetrating the eye and reaching the posterior segment—where retinal disorders arise—is enhanced. ODiN proposes the use of statin (STAs) loaded LNPs, while typically used to reduce cholesterol, STAs are being repurposed for their anti-inflammatory and antioxidant effects in eye diseases. Additionally, their poor water solubility makes them ideal candidates for encapsulation into lipid-based systems. ODiN will involve the design, formulation, and characterization of these novel LNPs. Furthermore ex vivo permeation studies of the LNPs under IOF conditions will be carried out using porcine eyes obtained from local slaughterhouses to evaluate penetration enhancement, thus implementing the 3Rs principle (Replacement, Reduction and Refinement). The final expected outcome is a novel and sustainable drug delivery system that may reduce the need for invasive treatments, with strong potential for translation into clinical applications.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI PARMA
Net EU contribution
€ 193 643,28
Address
VIA UNIVERSITA 12
43121 PARMA
Italy
Region
Nord-Est Emilia-Romagna Parma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)